ClinicalTrials.gg
CompletedNCT00474539Updated Mar 5, 2013Results posted

Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 7-valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 27 sites in Spain. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-03-05.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
449
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in Spain.

02

Conditions studied

  • Vaccines, Pneumococcal

Keywords

  • Vaccine
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2-month-old infants
  • Available for the entire study period

Exclusion criteria

Exclusion criteria:

  • Previous vaccination with any vaccine before the start of the study
  • Known to vaccination
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
449 participants (actual)

Study arms

  • Experimental
    1

    Biological: 13-valent pneumococcal conjugate vaccine

  • Active comparator
    2

    Biological: 7-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series

    Percentage of participants achieving a meningococcal C SBA serum antibody titer greater than or equal to (≥) 1:8 along with the corresponding 95% confidence interval (CI) are presented.

    Time frame: One month after infant series dose (at 5 months of age)

  2. Geometric Mean Titers (GMT) for Meningococcal C Antibodies in as Measured by Serum Bactericidal Assay (SBA) 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series and the Toddler Dose

    Time frame: One month after infant series dose 2 (at 5 months of age) and one month after toddler dose (at 16 months of age)

  3. Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose

    Predefined antibody levels for Diphtheria (0.01 or 0.1 International units \[IU\]/mL) and Tetanus (0.01 or 0.1 \[IU\]/mL).

    Time frame: One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)

  4. Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose

    Time frame: One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)

  5. Percentage of Participants Achieving Antibody Level ≥ 0.35μg/mL in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose

    Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)

  6. Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose

    GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMCs (13vPnC) were calculated for each pneumococcal serotype and timepoint, and 2-sided, 95% CI were constructed.

    Time frame: One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)

Secondary outcomes

  1. Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

    Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥ 1:8 along with the corresponding 95% confidence interval (CI) are presented.

    Time frame: One month after toddler dose (at 16 months of age)

Other outcomes

  1. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig)(present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (Sev) (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  2. Percentage of Participants Reporting Pre-Specified Systemic Events

    Systemic events (fever \[Fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased (Decr) appetite, irritability, increased (Incr) sleep, decreased sleep, hives, use of medication (Meds) to treat symptoms (Sx), and use of medication to prevent symptoms were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

07

Results

Posted Mar 5, 2013

Participant flow

Participants were recruited in Spain from 4 July 2007 to 23 July 2007.

Infant Series
Participant flow — Infant Series
Milestone13vPnC7vPnC
Started223226
Vaccinated dose 1218226
Vaccinated dose 2217222
Vaccinated dose 3214221
Completed213220
Not completed106
Withdrew: Withdrawal by subject34
Withdrew: Randomization error50
Withdrew: Lost to follow-up21
Withdrew: Protocol violation01
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC7vPnC
Started213220
Completed209220
Not completed40
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject10
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC7vPnC
Started209220
Completed208220
Not completed10
Withdrew: Protocol violation10

Outcome measures

PrimaryPercentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series

Percentage of participants achieving a meningococcal C SBA serum antibody titer greater than or equal to (≥) 1:8 along with the corresponding 95% confidence interval (CI) are presented.

Time frame:
One month after infant series dose (at 5 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series
percentage of participants13vPnC After Infant Series Dose 27vPnC After Infant Series Dose 2
Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series98.5 (95.8 to 99.7)99.1 (96.7 to 99.9)
Statistical analysis
  • 13vPnC After Infant Series Dose 2 vs 7vPnC After Infant Series Dose 2 · Difference: -0.5 · 95% CI -3.3 to 2.0
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions

Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig)(present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (Sev) (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions
percentage of participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC Toddler Dose7vPnC Toddler Dose
Tenderness-Any (n=199,205,182,180,170,175,164,172)21.118.521.416.110.614.328.726.7
Tenderness-Sig (n=199,200,177,177,167,169,154,160)3.04.01.14.01.21.22.63.8
Swelling-Any (n=196,200,182,177,171,170,169,168)13.314.522.014.723.420.026.618.5
Swelling-Mild (n=196,200,182,177,171,170,166,168)12.213.020.313.020.517.122.916.0
Swelling-Mod (n=196,196,177,175,166,168,156,163)2.62.02.32.36.66.09.05.5
Swelling-Sev (n=196,196,177,175,166,168,152,156)0.00.00.00.00.00.00.00.0
Redness-Any (n=197,199,181,180,172,172,170,169)15.215.123.820.026.722.730.023.1
Redness-Mild (n=197,198,180,180,172,171,167,165)14.714.122.219.424.421.128.121.2
Redness-Mod (n=196,197,178,175,166,169,157,163)0.51.02.21.13.63.69.66.7
Redness-Sev (n=196,196,177,175,166,168,152,156)0.00.00.00.00.60.00.00.0
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events

Systemic events (fever \[Fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased (Decr) appetite, irritability, increased (Incr) sleep, decreased sleep, hives, use of medication (Meds) to treat symptoms (Sx), and use of medication to prevent symptoms were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events
percentage of participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC Toddler Dose7vPnC Toddler Dose
Fv ≥38°C, ≤39°C(n=201,204,181,189,172,176,156,169)22.919.632.641.820.929.031.434.3
Fv >39°C, ≤40°C(n=196,196,177,176,166,168,154,156)1.00.51.71.13.63.04.52.6
Fv >40°C (n=196,197,177,175,166,168,152,156)0.00.50.00.00.00.00.70.0
Decr appetite (n=204,207,189,191,178,178,163,178)31.435.746.644.037.136.031.941.0
Irritability (n=202,211,192,190,179,188,171,179)46.549.857.360.043.039.441.553.6
Incr sleep (n=204,206,189,187,175,174,162,165)38.739.339.236.421.127.016.724.8
Decr sleep (n=196,204,183,187,175,178,162,166)19.427.527.327.822.925.319.818.7
Meds-treat sx (n=205,209,193,197,175,189,165,177)41.044.554.457.939.442.950.346.9
Meds-prevent sx(n=201,210,194,196,177,185,168,177)41.345.747.949.544.640.543.541.8
PrimaryGeometric Mean Titers (GMT) for Meningococcal C Antibodies in as Measured by Serum Bactericidal Assay (SBA) 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series and the Toddler Dose
Time frame:
One month after infant series dose 2 (at 5 months of age) and one month after toddler dose (at 16 months of age)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMT) for Meningococcal C Antibodies in as Measured by Serum Bactericidal Assay (SBA) 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series and the Toddler Dose
titer13vPnC After Infant Series Dose 27vPnC After Infant Series Dose 213vPnC After Toddler Dose7vPnC After Toddler Dose
Geometric Mean Titers (GMT) for Meningococcal C Antibodies in as Measured by Serum Bactericidal Assay (SBA) 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series and the Toddler Dose654.55 (557.75 to 768.16)757.04 (648.45 to 883.81)2573.06 (2176.29 to 3042.16)2098.12 (1779.65 to 2473.58)
Statistical analysis
  • 13vPnC After Infant Series Dose 2 vs 7vPnC After Infant Series Dose 2 · Ratio: 0.86 · 95% CI 0.69 to 1.08
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 1.23 · 95% CI 0.97 to 1.55
PrimaryPercentage of Participants Achieving Predefined Antibody Levels for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose

Predefined antibody levels for Diphtheria (0.01 or 0.1 International units \[IU\]/mL) and Tetanus (0.01 or 0.1 \[IU\]/mL).

Time frame:
One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose
percentage of participants13vPnC After Infant Series Dose 37vPnC After Infant Series Dose 313vPnC After Toddler Dose7vPnC After Toddler Dose
Diphtheria ≥0.10 IU/mL98.5 (95.6 to 99.7)99.1 (96.6 to 99.9)100.0 (97.8 to 100.0)100.0 (97.9 to 100.0)
Diphtheria ≥0.01 IU/mL100.0 (98.1 to 100.0)100.0 (98.3 to 100.0)100.0 (97.8 to 100.0)100.0 (97.9 to 100.0)
Tetanus ≥0.10 IU/mL96.6 (92.6 to 98.7)96.7 (93.0 to 98.8)100.0 (97.8 to 100.0)100.0 (97.9 to 100.0)
Tetanus ≥0.01 IU/mL100.0 (97.9 to 100.0)100.0 (98.0 to 100.0)100.0 (97.8 to 100.0)100.0 (97.9 to 100.0)
Statistical analysis
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Difference: -0.6 · 95% CI -3.5 to 2.0
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Difference: 0.0 · 95% CI -1.9 to 1.7
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Difference: -0.2 · 95% CI -4.4 to 4.0
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Difference: 0.0 · 95% CI -2.1 to 2.0
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.0 · 95% CI -2.2 to 2.2
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.0 · 95% CI -2.2 to 2.2
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.0 · 95% CI -2.3 to 2.2
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.0 · 95% CI -2.3 to 2.2
PrimaryGeometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose
Time frame:
One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Reported as:
Geometric mean · IU/mL
Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose
IU/mL13vPnC After Infant Series Dose 37vPnC After Infant Series Dose 313vPnC After Toddler Dose7vPnC After Toddler Dose
Diphtheria0.79 (0.69 to 0.90)0.92 (0.81 to 1.04)3.00 (2.63 to 3.41)3.23 (2.88 to 3.63)
Tetanus1.10 (0.94 to 1.27)1.20 (1.04 to 1.39)3.29 (2.83 to 3.83)3.28 (2.83 to 3.79)
Statistical analysis
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 0.86 · 95% CI 0.72 to 1.03
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 0.91 · 95% CI 0.74 to 1.12
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.93 · 95% CI 0.78 to 1.10
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 1.00 · 95% CI 0.81 to 1.24
PrimaryPercentage of Participants Achieving Antibody Level ≥ 0.35μg/mL in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose

Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥ 0.35μg/mL in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose
percentage of participants13vPnC After Infant Series Dose 213vPnC After Infant Series Dose 313vPnC After Toddler Dose
Common Serotypes - Serotype 492.5 (87.9 to 95.7)98.5 (95.7 to 99.7)100.0 (97.7 to 100.0)
Common Serotypes - Serotype 6B27.9 (21.8 to 34.7)94.9 (90.9 to 97.5)100.0 (97.7 to 100.0)
Common Serotypes - Serotype 9V89.9 (84.8 to 93.7)97.0 (93.5 to 98.9)99.3 (96.3 to 100.0)
Common Serotypes - Serotype 1491.0 (86.1 to 94.6)97.0 (93.6 to 98.9)99.4 (96.6 to 100.0)
Common Serotypes - Serotype 18C88.9 (83.7 to 92.9)99.0 (96.4 to 99.9)98.8 (95.6 to 99.8)
Common Serotypes - Serotype 19F100.0 (98.2 to 100.0)99.0 (96.4 to 99.9)98.7 (95.5 to 99.8)
Common Serotypes - Serotype 23F55.8 (48.6 to 62.8)93.0 (88.5 to 96.1)98.1 (94.7 to 99.6)
Additional Serotypes - Serotype 196.0 (92.2 to 98.2)98.5 (95.7 to 99.7)98.8 (95.6 to 99.8)
Additional Serotypes - Serotype 373.8 (67.1 to 79.9)86.2 (80.5 to 90.7)93.6 (88.6 to 96.9)
Additional Serotypes - Serotype 586.4 (80.8 to 90.8)96.0 (92.2 to 98.2)100.0 (97.6 to 100.0)
Additional Serotypes - Serotype 6A80.8 (74.6 to 86.0)99.0 (96.4 to 99.9)99.4 (96.5 to 100.0)
Additional Serotypes - Serotype 7F94.5 (90.3 to 97.2)100.0 (98.2 to 100.0)99.4 (96.5 to 100.0)
Additional Serotypes - Serotype 19A92.9 (88.4 to 96.1)99.5 (97.2 to 100.0)100.0 (97.5 to 100.0)
PrimaryGeometric Mean Antibody Concentration (GMC) in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose

GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMCs (13vPnC) were calculated for each pneumococcal serotype and timepoint, and 2-sided, 95% CI were constructed.

Time frame:
One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose
μg/mL13vPnC After Infant Series Dose 213vPnC After Infant Series Dose 313vPnC After Toddler Dose
Common Serotypes - Serotype 41.55 (1.35 to 1.78)2.32 (2.08 to 2.60)3.88 (3.42 to 4.40)
Common Serotypes - Serotype 6B0.21 (0.18 to 0.25)2.59 (2.20 to 3.05)12.25 (10.78 to 13.92)
Common Serotypes - Serotype 9V1.15 (1.01 to 1.32)1.51 (1.35 to 1.68)2.67 (2.34 to 3.05)
Common Serotypes - Serotype 141.94 (1.64 to 2.29)4.51 (3.89 to 5.22)9.82 (8.54 to 11.30)
Common Serotypes - Serotype 18C1.30 (1.11 to 1.51)1.86 (1.68 to 2.07)2.29 (2.01 to 2.61)
Common Serotypes - Serotype 19F2.98 (2.60 to 3.41)2.46 (2.21 to 2.74)6.11 (5.21 to 7.16)
Common Serotypes - Serotype 23F0.40 (0.34 to 0.48)1.67 (1.44 to 1.94)3.96 (3.43 to 4.59)
Additional Serotypes - Serotype 11.87 (1.61 to 2.16)2.95 (2.61 to 3.33)4.60 (3.94 to 5.37)
Additional Serotypes - Serotype 30.54 (0.48 to 0.61)0.85 (0.76 to 0.95)1.04 (0.91 to 1.19)
Additional Serotypes - Serotype 50.88 (0.77 to 1.00)1.83 (1.62 to 2.06)3.69 (3.26 to 4.18)
Additional Serotypes - Serotype 6A0.81 (0.70 to 0.95)3.08 (2.76 to 3.44)7.71 (6.75 to 8.80)
Additional Serotypes - Serotype 7F1.51 (1.33 to 1.71)3.41 (3.11 to 3.74)5.66 (4.90 to 6.53)
Additional Serotypes - Serotype 19A1.52 (1.31 to 1.76)2.50 (2.27 to 2.75)10.21 (8.92 to 11.68)
SecondaryPercentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥ 1:8 along with the corresponding 95% confidence interval (CI) are presented.

Time frame:
One month after toddler dose (at 16 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
percentage of participants13vPnC After Toddler Dose7vPnC After Toddler Dose
Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose100.0 (97.8 to 100.0)99.4 (96.80 to 100.0)
Statistical analysis
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.6 · 95% CI -1.7 to 3.2

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Infant Series—6/218 (2.8%)204/218 (93.6%)
7vPnC Infant Series—8/226 (3.5%)211/225 (93.8%)
13vPnC Post-Infant Series—9/218 (4.1%)6/218 (2.8%)
7vPnC Post-Infant Series—6/226 (2.7%)13/225 (5.8%)
13vPnC Toddler Series—1/218 (0.5%)171/209 (81.8%)
7vPnC Toddler Series—0/226 (0%)179/218 (82.1%)
13vPnC 6-Month Follow-up—4/218 (1.8%)4/218 (1.8%)
7vPnC 6-Month Follow-up—9/226 (4%)2/224 (0.9%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
BronchiolitisInfections and infestations1/2182/2262/2180/2260/2180/2260/2180/226
PneumoniaInfections and infestations1/2180/2261/2181/2260/2180/2262/2180/226
GastroenteritisInfections and infestations1/2181/2260/2181/2260/2180/2260/2182/226
AsthmaRespiratory, thoracic and mediastinal disorders0/2180/2261/2180/2260/2180/2260/2180/226
BronchitisInfections and infestations0/2180/2261/2180/2260/2180/2260/2180/226
BronchospamsRespiratory, thoracic and mediastinal disorders0/2180/2260/2180/2260/2180/2261/2180/226
ConvulsionNervous system disorders0/2180/2261/2180/2261/2180/2260/2180/226
DiarrhoeaGastrointestinal disorders0/2180/2261/2180/2260/2180/2260/2181/226
Enterocolitis viralInfections and infestations0/2180/2261/2180/2260/2180/2260/2180/226
Escherichia urinary tract infectionInfections and infestations1/2180/2260/2180/2260/2180/2260/2180/226
Most frequent other events
Showing 10 of 137
Most frequent other events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
IrritabilityGeneral disorders202/218211/225——171/209179/218——
Decreased appetiteGeneral disorders204/218207/225——163/209178/218——
Increased sleepGeneral disorders204/218206/225——162/209165/218——
Fever ≥38°C but ≤39°CGeneral disorders201/218204/225——156/209169/218——
Tenderness (any)Skin and subcutaneous tissue disorders199/218205/225——164/209172/218——
Tenderness (significant)Skin and subcutaneous tissue disorders199/218200/225——154/209160/218——
Decreased sleepGeneral disorders196/218204/225——162/209166/218——
Erythema (any)Skin and subcutaneous tissue disorders197/218199/225——170/209169/218——
Erythema (mild)Skin and subcutaneous tissue disorders197/218198/225——167/209165/218——
Induration (any)Skin and subcutaneous tissue disorders196/218200/225——169/209168/218——

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC7vPnCTotal
Mean2.1 ± 0.42.0 ± 0.42.1 ± 0.4
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC7vPnCTotal
Female104116220
Male115109224
08

Study locations

27 sites
  • Almeria, 4007, Spain
  • Almeria, 4009, Spain
  • Almeria, 4120, Spain
  • Barcelona, 8195, Spain
  • Barcelona, 8930, Spain
  • Coruna, 15270, Spain
  • Coruna, 15405, Spain
  • Madrid, 28041, Spain
  • Madrid, 28900, Spain
  • Madrid, 28922, Spain
  • Madrid, 28942, Spain
  • Malaga, 29015, Spain
  • Malaga, 29200, Spain
  • Ourense, 32005, Spain
  • Pamplona, 31008, Spain
  • Santiago de Compostela, 15706, Spain
  • Seville, 41013, Spain
  • Valencia, 46008, Spain
  • Valencia, 46011, Spain
  • Valencia, 46021, Spain
  • Valencia, 46022, Spain
  • Valencia, 46023, Spain
  • Valencia, 46024, Spain
  • Valencia, 46183, Spain
  • Valencia, 46200, Spain
  • Valencia, 46930, Spain
  • Vigo, 36204, Spain
09

References and documents

Publications

  • Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinon-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine. 2013 Oct 1;31(42):4765-74. doi: 10.1016/j.vaccine.2013.08.009. Epub 2013 Aug 16. PubMed 23965217 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2007
First posted
May 17, 2007
Start
Jul 2007
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Mar 5, 2013
Last update
Mar 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00474539
Responsible party
Sponsor
First posted
May 17, 2007
Start date
Jul 2007
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Mar 5, 2013
Last update
Mar 5, 2013

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Spain: infomed@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion